Evaluating the Efficacy of Primary Treatment for Graves’ Disease Complicated by Thyrotoxic Periodic Paralysis
Table 1
A comparison of patient demographics and treatment outcome between patients who had antithyroid drugs (ATD), radioactive iodine (RAI), and surgery as the primary treatment for Graves’ disease with thyrotoxic periodic paralysis (TPP).
Number (%)/median (range)
value
Total ()
ATD ()
RAI ()
Surgery ()
Gender (male : female)
15 : 1
8 : 0
4 : 0
3 : 1
0.202
Age (years)
28 (17–45)
26.0 (17–33)
36 (23–42)
30.5 (26–45)
—
Smoker
10 (62.5%)
4 (50%)
2 (50%)
4 (100%)
0.202
Drinker
6 (37.5%)
2 (25%)
1 (25%)
3 (75%)
0.202
Body weight (kg)
69.9 (45.0–105)
70.9 (61–87)
66.5 (63–105)
74.5 (45–82)
—
Family history of thyrotoxicosis
4 (25.0%)
1 (12.5%)
2 (50.0%)
1 (25%)
0.368
TPP as the initial thyrotoxicosis symptom
13 (81.3%)
5 (62.5%)
4 (100%)
4 (100%)
0.158
Presence of severe Graves’ ophthalmopathy*
2 (12.5%)
1 (12.5%)
0 (0.0%)
1 (25%)
0.565
Antithyroglobulin antibodies (<100 L/titre)
1088 (63–6400)
413 (63–1600)
3276 (100–6400)
81 (63–100)
—
Antithyroid microsomal antibodies (<100 L/titre)
3325 (100–6400)
300 (100–400)
6400 (6400–6400)
3250 (100–6400)
—
Outcome after primary treatment
Recurrence of thyrotoxicosis
10 (62.5%)
8 (100%)
2 (50%)
0 (0%)
0.003
Recurrence of TPP
4 (25.0%)
4 (50%)
0 (0%)
0 (0%)
0.069
Hypothyroidism requiring replacement
12 (75.0%)
6 (75.0%)
2 (50%)
4 (100%)
0.264
Although all patients had mild eye signs, only two patients had severe eye signs and required ophthalmic treatment for their eye condition.
